Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana O Hoff

Showing results (41-50 of 74) with videos related to

Pageof 8
Sort By:
The Journal of Clinical Investigation|December 19, 2002
Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin geneAna O Hoff, Philip Catala-Lehnen, Pamela M Thomas, et al.
The Journal of Clinical Endocrinology and Metabolism|July 9, 2004
A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinomaCamilo Jimenez, Gerald T Dang, Pamela N Schultz, et al.
Arquivos Brasileiros De Endocrinologia E Metabologia|July 14, 2010
[Importance of parathyroid SPECT and 99mTc scintigraphy, and of clinical, laboratorial, ultrasonographic and citologic correlation in the pre-operative localization of the parathyroid adenoma - pictorial assay]Marco Antônio Condé de Oliveira, Sérgio Setsuo Maeda, Patrícia Dreyer, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 19, 2008
Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonatesAna O Hoff, Béla B Toth, Kadri Altundag, et al.
Arquivos Brasileiros De Endocrinologia E Metabologia|January 27, 2009
Early diagnosis of multiple endocrine neoplasia type 2B: a challenge for physiciansCleber P Camacho, Ana O Hoff, Susan C Lindsey, et al.
Cancer|October 19, 2022
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trialMarcia S Brose, Bruce G Robinson, Steven I Sherman, et al.
The Lancet. Oncology|July 8, 2021
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trialMarcia S Brose, Bruce Robinson, Steven I Sherman, et al.
Archives of Endocrinology and Metabolism|May 24, 2018
Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancerDebora L S Danilovic, Gilberto Castro, Felipe S R Roitberg, et al.
Thyroid : Official Journal of the American Thyroid Association|December 8, 2023
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 StudyJaume Capdevila, Jolanta Krajewska, Jorge Hernando, et al.
Frontiers in Oncology|July 11, 2025
Case Report: Cardiac myxomas and Carney complex: a case of recurrent embolic strokes and intracranial tumor growthAliny W Kuhn, Antonio M Lerario, Alice N R Morais, et al.
Pageof 8

Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
The Journal of Clinical Investigation|December 19, 2002
Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin geneAna O Hoff, Philip Catala-Lehnen, Pamela M Thomas, et al.
The Journal of Clinical Endocrinology and Metabolism|July 9, 2004
A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinomaCamilo Jimenez, Gerald T Dang, Pamela N Schultz, et al.
Arquivos Brasileiros De Endocrinologia E Metabologia|July 14, 2010
[Importance of parathyroid SPECT and 99mTc scintigraphy, and of clinical, laboratorial, ultrasonographic and citologic correlation in the pre-operative localization of the parathyroid adenoma - pictorial assay]Marco Antônio Condé de Oliveira, Sérgio Setsuo Maeda, Patrícia Dreyer, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 19, 2008
Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonatesAna O Hoff, Béla B Toth, Kadri Altundag, et al.
Arquivos Brasileiros De Endocrinologia E Metabologia|January 27, 2009
Early diagnosis of multiple endocrine neoplasia type 2B: a challenge for physiciansCleber P Camacho, Ana O Hoff, Susan C Lindsey, et al.
Cancer|October 19, 2022
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trialMarcia S Brose, Bruce G Robinson, Steven I Sherman, et al.
The Lancet. Oncology|July 8, 2021
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trialMarcia S Brose, Bruce Robinson, Steven I Sherman, et al.
Archives of Endocrinology and Metabolism|May 24, 2018
Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancerDebora L S Danilovic, Gilberto Castro, Felipe S R Roitberg, et al.
Thyroid : Official Journal of the American Thyroid Association|December 8, 2023
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 StudyJaume Capdevila, Jolanta Krajewska, Jorge Hernando, et al.
Frontiers in Oncology|July 11, 2025
Case Report: Cardiac myxomas and Carney complex: a case of recurrent embolic strokes and intracranial tumor growthAliny W Kuhn, Antonio M Lerario, Alice N R Morais, et al.
Pageof 8